Skip to main
RLAY
RLAY logo

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics Inc. is poised for a favorable market position due to the promising clinical data from its medicine candidate RLY-2608, which shows improved efficacy and tolerability profiles compared to the existing PI3Ka inhibitor, capivasertib. This enhancement is expected to drive rapid market uptake, potentially increasing the penetration of PI3Ka inhibitors and expanding the market for these therapies significantly. Given that capivasertib has already expanded the market to approximately $700 million, the advancements with RLY-2608 could lead to further substantial revenue opportunities for Relay Therapeutics.

Bears say

Relay Therapeutics Inc's stock outlook is negatively impacted by a significant reduction in the expected median progression-free survival (mPFS) for their product candidates, dropping approximately 80% from 24 months to just 5 months, which raises concerns regarding the efficacy of their therapies. Additionally, safety liabilities related to inavolisib’s inhibition of wt-PI3Ka—particularly in patients with metabolic unfitness—have led to a disappointing commercial launch, failing to meet expectations for a first-line treatment. Competitive pressures in the market, exemplified by declining sales for Piqray, further illustrate the challenging environment Relay Therapeutics faces as it seeks to establish its products in the precision oncology space.

RLAY has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 8 analysts, RLAY has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.